A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Rates of cognitive decline in Alzheimer’s disease (AD) are extremely heterogeneous, with ages of symptom onset ranging from age 40-100 years and conversion from mild cognitive impairment to AD dementia taking 2-20 years. Development of biomarkers for amyloid-beta (Aβ) and tau protein aggregates, the hallmark pathologies of AD, have improved patient monitoring/stratification and drug development, but they still only explain 20-40% of the variance in cognitive impairment (CI) in AD. To discover additional molecular drivers and biomarkers of AD dementia, we perform cerebrospinal fluid (CSF) proteomics on 3,416 individuals from six deeply phenotyped prospective AD case-control cohorts. We identify synapse proteins as the strongest correlates of CI, independent of Aβ and tau. Using machine learning we derive the CSF YWHAG:NPTX2 synapse protein ratio, a robust correlate of CI, which explains 27% of the variance in CI beyond CSF PTau181:Aβ42, 10% beyond tau PET, and 50% beyond CSF NfL in Aβ positive individuals. We find YWHAG:NPTX2 also increases with normal aging as early as age 20 and increases at a faster rate in APOE4 carriers and autosomal dominant-AD mutation carriers. Most notably, YWHAG:NPTX2+ individuals (top 25 th percentile) are 15-times (HR=15.4 [10.6-22.2]) more likely to experience cognitive decline over 15 years compared to YWHAG:NPTX2– individuals (bottom 25 th percentile), and this rises to 19-times (HR=18.9 [10.83-32.9]) with additional stratification by Aβ and phosphorylated tau status. Lastly, we perform plasma proteomics on 4,245 individuals to develop a plasma-based signature of CI which partly recapitulates CSF YWHAG:NPTX2. Overall, our findings underscore CSF YWHAG:NPTX2 and the corresponding plasma signature as robust prognostic biomarkers for AD onset and progression beyond gold-standard biomarkers of Aβ, tau, and neurodegeneration and implicate synapse dysfunction as a core driver of AD dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SciPy 1.0: fundamental algorithms for scientific computing in Python
Virtanen, P., Gommers, R., Oliphant, T. E., Haberland, M., Reddy, T., Cournapeau, D., Burovski, E., Peterson, P., Weckesser, W., Bright, J., et al. (2020) · Nature Methods · doi:10.1038/s41592-019-0686-2 · Cited by 38,430
Harris, C. R., Millman, K. J., van der Walt, S. J., Gommers, R., Virtanen, P., Cournapeau, D., Wieser, E., Taylor, J., Berg, S., Smith, N. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2649-2 · Cited by 23,826
SciPy 1.0: fundamental algorithms for scientific computing in Python
Virtanen, P., Gommers, R., Oliphant, T. E., Haberland, M., Reddy, T., Cournapeau, D., Burovski, E., Peterson, P., Weckesser, W., Bright, J., et al. (2019) · Apollo - University of Cambridge Repository · doi:10.17863/cam.64134 · Cited by 10,460
seaborn: statistical data visualization
Waskom, M. (2021) · Journal of Open Source Software · doi:10.21105/joss.03021 · Cited by 7,310
Raudvere, U., Kolberg, L., Kuzmin, I., Arak, T., Adler, P., Peterson, H., & Vilo, J. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz369 · Cited by 5,045
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Self-citationKnopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015004 · Cited by 1,754
Mitchell, A. J., & Shiri‐Feshki, M. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01326.x · Cited by 1,659 · cited 1×
“…nature of case– control studies, assuming ~20 years for progression from Aβ + cognitively normal to AD dementia based on population-based studies 37,38 , our data suggest that AD progression mimics 82 years of ‘normal’ age-related increases in YWHAG:NPTX2, representing a stark 4.1-time increase…”
InfluentialPalmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603
Self-citationNeuropathology of older persons without cognitive impairment from two community-based studies
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336 · cited 1×
“Clinical and neuropathological data collection has been reported in detail elsewhere 10,65–68 .”
Self-citationReligious Orders Study and Rush Memory and Aging Project
Bennett, D. A., Buchman, A. S., Boyle, P. A., Barnes, L. L., Wilson, R. S., & Schneider, J. A. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179939 · Cited by 1,260 · cited 1×
“All ROSMAP participants enrolled without known dementia and agreed to detailed clinical evaluation and brain donation at death 64 .”
Self-citationBiomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159
Self-citationThe ageing cortical synapse: hallmarks and implications for cognitive decline
Morrison, J. H., & Baxter, M. G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3200 · Cited by 965 · cited 1×
“Second, synapse dysfunction, morphological alterations and loss, rather than overt neuron loss, are major hallmarks of mammalian brain aging that are closely linked with age-related cognitive decline in nonhuman primates 51 .”
SynGO: An Evidence-Based, Expert-Curated Knowledge Base for the Synapse
Koopmans, F., van Nierop, P., Andres-Alonso, M., Byrnes, A., Cijsouw, T., Coba, M. P., Cornelisse, L. N., Farrell, R. J., Goldschmidt, H. L., Howrigan, D. P., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.05.002 · Cited by 938
Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study
Hanseeuw, B. J., Betensky, R. A., Jacobs, H. I. L., Schultz, A. P., Sepulcre, J., Becker, J. A., Cosio, D. M. O., Farrell, M., Quiroz, Y. T., Mormino, E. C., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1424 · Cited by 865
Self-citationNeuronal activity enhances tau propagation and tau pathology in vivo
Wu, J. W., Hussaini, S. A., Bastille, I. M., Rodriguez, G. A., Mrejeru, A., Rilett, K., Sanders, D. W., Cook, C., Fu, H., Boonen, R. A. C. M., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4328 · Cited by 820 · cited 2×
“Lastly, neuronal hyperactivity enhances tau propagation 40 , which aligns with the positive association between YWHAG:NPTX2 and future Aβ-driven tau PET.”
Mapping Scores Onto Stages: Mini-Mental State Examination and Clinical Dementia Rating
Perneczky, R., Wagenpfeil, S., Komossa, K., Grimmer, T., Diehl, J., & Kurz, A. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000192478.82189.a8 · Cited by 768
Organ aging signatures in the plasma proteome track health and disease
Oh, H. S.-H., Rutledge, J., Nachun, D., Pálovics, R., Abiose, O., Moran-Losada, P., Channappa, D., Urey, D. Y., Kim, K., Sung, Y. J., et al. (2023) · Nature · doi:10.1038/s41586-023-06802-1 · Cited by 634
Self-citationMostafavi, S., Gaiteri, C., Sullivan, S. E., White, C. C., Tasaki, S., Xu, J., Taga, M., Klein, H.-U., Patrick, E., Komashko, V., et al. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0154-9 · Cited by 509
Self-citationPlasma protein patterns as comprehensive indicators of health
Williams, S. A., Kivimaki, M., Langenberg, C., Hingorani, A. D., Casas, J. P., Bouchard, C., Jonasson, C., Sarzynski, M. A., Shipley, M. J., Alexander, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0665-2 · Cited by 506 · cited 1×
“The SomaLogic (https://somalogic.com/) SomaScan assay 72,73 , which uses slow off-rate modified DNA aptamers (SOMAmers) to bind target proteins with high specificity, was used to quantify the relative concentration of thousands of human proteins in plasma and CSF in the Stanford, Knight-ADRC, ADNI,…”
Symptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis
Ryman, D. C., Acosta-Baena, N., Aisen, P. S., Bird, T., Danek, A., Fox, N. C., Goate, A., Frommelt, P., Ghetti, B., Langbaum, J. B. S., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000596 · Cited by 502 · cited 1×
“ADAD mutations have varying degrees of severity, with estimated ages at symptom onset ranging from 25 to 65 years depending on the mutation 25,36 .”
Mathys, H., Peng, Z., Boix, C. A., Victor, M. B., Leary, N., Babu, S., Abdelhady, G., Jiang, X., Ng, A. P., Ghafari, K., et al. (2023) · Cell · doi:10.1016/j.cell.2023.08.039 · Cited by 495 · cited 2×
“In human brains, the NPTX2 mRNA and protein are downregulated in AD neurons based on single-cell RNA sequencing, immunohistochemistry and bulk proteomics 28,29 , suggesting that its decrease with CI in AD CSF may reflect decreased expression.”
Self-citationBiomarker Changes during 20 Years Preceding Alzheimer’s Disease
Jia, J., Ning, Y., Chen, M., Wang, S., Yang, H., Li, F., Ding, J., Li, Y., Zhao, B., Lyu, J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2310168 · Cited by 455
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
Dujardin, S., Commins, C., Lathuiliere, A., Beerepoot, P., Fernandes, A. R., Kamath, T. V., De Los Santos, M. B., Klickstein, N., Corjuc, D. L., Corjuc, B. T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0938-9 · Cited by 438 · cited 1×
“Rates of cognitive decline in AD are extremely heterogeneous, with symptom onset occurring between the ages of 40 and 100 years and conversion from mild cognitive impairment (MCI) to AD dementia occurring in 2–20 years 2 .”
Integrated multimodal cell atlas of Alzheimer’s disease
Gabitto, M. I., Travaglini, K. J., Rachleff, V. M., Kaplan, E. S., Long, B., Ariza, J., Ding, Y., Mahoney, J. T., Dee, N., Goldy, J., et al. (2023) · doi:10.1101/2023.05.08.539485 · Cited by 425
Integrated multimodal cell atlas of Alzheimer’s disease
Gabitto, M. I., Travaglini, K. J., Rachleff, V. M., Kaplan, E. S., Long, B., Ariza, J., Ding, Y., Mahoney, J. T., Dee, N., Goldy, J., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01774-5 · Cited by 397 · cited 9×
“We then tested whether YWHAG:NPTX2 could predict dementia onset in A+T 1 + cognitively normal individuals, adjusting for pTau 181 :Aβ 42 , CSF NfL, CSF Ng, age, sex and APOE4 dose (the Stanford cohort was not included because of a low event sample size, total n = 171).”
InfluentialThe clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
the Synaptic Health Endpoints Working Group, Colom-Cadena, M., Spires-Jones, T., Zetterberg, H., Blennow, K., Caggiano, A., DeKosky, S. T., Fillit, H., Harrison, J. E., Schneider, L. S., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00588-4 · Cited by 328
Self-citationAttributable risk of Alzheimer's dementia attributed to age-related neuropathologies
Boyle, P. A., Yu, L., Leurgans, S. E., Wilson, R. S., Brookmeyer, R., Schneider, J. A., & Bennett, D. A. (2019) · Annals of Neurology · doi:10.1002/ana.25380 · Cited by 318
Self-citationNarp regulates homeostatic scaling of excitatory synapses on parvalbumin-expressing interneurons
Chang, M. C., Park, J. M., Pelkey, K. A., Grabenstatter, H. L., Xu, D., Linden, D. J., Sutula, T. P., McBain, C. J., & Worley, P. F. (2010) · Nature Neuroscience · doi:10.1038/nn.2621 · Cited by 316 · cited 1×
“The most downregulated protein was NPTX2, encoded by an immediate early gene that regulates homeostatic scaling of excitatory synapses on parvalbumin interneurons 26 to prevent neuronal network hyperactivity 27 .”
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
Horie, K., Salvadó, G., Barthélemy, N. R., Janelidze, S., Li, Y., He, Y., Saef, B., Chen, C. D., Jiang, H., Strandberg, O., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02443-z · Cited by 249
Self-citationPelkey, K. A., Barksdale, E., Craig, M. T., Yuan, X., Sukumaran, M., Vargish, G. A., Mitchell, R. M., Wyeth, M. S., Petralia, R. S., Chittajallu, R., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.02.020 · Cited by 245
Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer’s disease
Pooler, A. M., Polydoro, M., Maury, E. A., Nicholls, S. B., Reddy, S. M., Wegmann, S., William, C., Saqran, L., Cagsal-Getkin, O., Pitstick, R., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0199-x · Cited by 236
Large-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk
Walker, K. A., Chen, J., Zhang, J., Fornage, M., Yang, Y., Zhou, L., Grams, M. E., Tin, A., Daya, N., Hoogeveen, R. C., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00064-0 · Cited by 212
Self-citationCerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s disease
Johnson, E. C. B., Bian, S., Haque, R. U., Carter, E. K., Watson, C. M., Gordon, B. A., Ping, L., Duong, D. M., Epstein, M. P., McDade, E., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02476-4 · Cited by 170 · cited 2×
“Notably, SMOC1, an extracellular matrix protein previously linked to AD and Aβ plaques 24,25 , was not associated with CI after pTau 181 :Aβ 42 adjustment (Extended Data Fig.”
Self-citationZhou, J., Wade, S. D., Graykowski, D., Xiao, M.-F., Zhao, B., Giannini, L. A. A., Hanson, J. E., van Swieten, J. C., Sheng, M., Worley, P. F., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf0141 · Cited by 152
Sathe, G., Na, C. H., Renuse, S., Madugundu, A. K., Albert, M., Moghekar, A., & Pandey, A. (2019) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201800105 · Cited by 126
Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
Nilsson, J., Gobom, J., Sjödin, S., Brinkmalm, G., Ashton, N. J., Svensson, J., Johansson, P., Portelius, E., Zetterberg, H., Blennow, K., et al. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12179 · Cited by 82
Self-citationTimsina, J., Gomez-Fonseca, D., Wang, L., Do, A., Western, D., Alvarez, I., Aguilar, M., Pastor, P., Henson, R. L., Herries, E., et al. (2022) · Journal of Alzheimer’s Disease · doi:10.3233/jad-220399 · Cited by 68
Self-citationAli, M., Timsina, J., Western, D., Liu, M., Beric, A., Budde, J., Do, A., Heo, G., Wang, L., Gentsch, J., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.02.014 · Cited by 61
Self-citationEstrogen Receptor Genes, Cognitive Decline, and Alzheimer Disease
Oveisgharan, S., Yang, J., Yu, L., Burba, D., Bang, W., Tasaki, S., Grodstein, F., Wang, Y., Zhao, J., De Jager, P. L., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000206833 · Cited by 53
Self-citationMartínez-Dubarbie, F., Guerra-Ruiz, A., López-García, S., Lage, C., Fernández-Matarrubia, M., Infante, J., Pozueta-Cantudo, A., García-Martínez, M., Corrales-Pardo, A., Bravo, M., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01319-1 · Cited by 47
Ali, M., Timsina, J., Wang, L., Do, A., Western, D., Sung, Y. J., & Cruchaga, C. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.077212 · Cited by 5
Self-citation
Cited by
New landscape of the diagnosis of Alzheimer’s disease
Frisoni, G. B., Hansson, O., Nichols, E., Garibotto, V., Schindler, S. E., van der Flier, W. M., Jessen, F., Villain, N., Arenaza-Urquijo, E. M., Crivelli, L., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01294-2 · Cited by 143
Self-citationGong, Z., Laporte, J. P., Guo, A. Y., Bilgel, M., Bae, J., Fox, N. Y., de Rouen, A., Zhang, N., Taranath, A., de Cabo, R., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci196638 · Cited by 7
Linden, A. K., Affaneh, A., Aylward, A., Wong, Y., Kessler, J. A., & Peng, C.-Y. (2025) · doi:10.64898/2025.12.14.694212 · Cited by 1
Metadata
- Authors
- Oh, H. S.-H., Urey, D. Y., Karlsson, L., Zhu, Z., Shen, Y., Farinas, A., Timsina, J., Duggan, M. R., Chen, J., Guldner, I. H., Morshed, N., Yang, C., Western, D., Ali, M., Le Guen, Y., Trelle, A., Herukka, S.-K., Rauramaa, T., Hiltunen, M., Lipponen, A., Luikku, A. J., Poston, K. L., Mormino, E., Wagner, A. D., Wilson, E. N., Channappa, D., Leinonen, V., Stevens, B., Ehrenberg, A. J., Gottesman, R. F., Coresh, J., Walker, K. A., Zetterberg, H., Bennett, D. A., Franzmeier, N., Hansson, O., Cruchaga, C., & Wyss-Coray, T.
- Venue
- Nature Medicine
- Published
- 2025-03-31
- Volume
- 31
- Issue
- 5
- Pages
- 1592-1603
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4409087059
- Cited by
- 121
- References
- 43
- FWCI
- 74.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.